Biogen Idec Inc., of Weston, Mass., blasted consensus sales estimates for multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) out of the water, turning in $192 million in its second quarter earnings, compared to the $75 million expected by the street. The company's total revenues were $1.7 billion for the second quarter, up 21 percent over the second quarter of 2012.